|
[1]SAMUEL D,MULLER R,ALEXANDER G,et al.Liver transplantation in European patients with the hepatitis B surface antigen[J].N Engl J Med,1993,329(25):1842-1847.
|
|
[2]KATZ LH,TUR-KASPA R,GUY DG,et al.Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation[J].Cochrane Database Syst Rev,2010,7:CD006005.
|
|
[3]ROSENAU J,KREUTZ T,KUJAWA M,et al.HBsA g level at time of liver transplantation determines HBsA g decrease and antiHBs increase and affects HBV DNA decrease during early immunoglobulin administration[J].J Hepatol,2007,46(4):635-644.
|
|
[4]CHU CJ,FONTANA RJ,MOORE C,et al.Outcome of liver transplantation for hepatitis B:report of a single center's experience[J].Liver Transpl,2001,7(8):724-731.
|
|
[5]NAOUMOV NV,LOPES AR,BURRA P,et al.Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation[J].J Hepatol,2001,34(6):888-894.
|
|
[6]PERRILLO RP,WRIGHT T,RAKELA J,et al.A multicenter U-nited States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B[J].Hepatology,2001,33(2):424-432.
|
|
[7]GU CH,WANG YM.Liver failure[M].Beijing:People's Medical Publishing House,2002:753-754.(in Chinese)顾长海,王宇明.肝功能衰竭[M].北京:人民卫生出版社,2002:753-754.
|
|
[8]SHEN ZY,ZHU ZJ,DENG YL,et al.Combination of low-dose HBIG and nucleoside analogues to prevent recurrent hepatitis B virus after liver transplantation:a retrospective analysis of 1506 cases[J].Chin J Hepatobiliary Surg,2011,17(5):364-366.(in Chinese)沈中阳,朱志军,邓永林,等.小剂量HBIG联合核苷类似物预防肝移植术后乙肝复发1506例回顾性分析[J].中华肝胆外科杂志,2011,17(5):364-366.
|
|
[9]WANG ZF,ZHU ZJ,SHEN ZY.Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation[J].Hepatobiliary Pancreat Dis Int,2005,4(4):509-514.
|
|
[10]UO Oxford.Oxford Centre for Evidence-based Medicine-Levels of Evidence(March 2009)[EB/OL]//http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidencemarch-2009/.
|
|
[11]BROZEK JL,AKL EA,JAESCHKE R,et al.Grading quality of evidence and strength of recommendations in clinical practice guidelines:Part 2 of 3.The GRADE approach to grading quality of evidence about diagnostic tests and strategies[J].Allergy,2009,64(8):1109-1116.
|
|
[12]TANDOI F,CAVIGLIA GP,PITTALUGA F,et al.Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers[J].Dig Liver Dis,2014,46(11):1020-1024.
|
|
[13]XIE M,RAO W,YANG T,et al.Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation[J].Liver Int,2015,35(3):897-904.
|
|
[14]HUSSAIN M,SOLDEVILA-PICO C,EMRE S,et al.Presence of intrahepatic(total and ccc)HBV DNA is not predictive of HBV recurrence after liver transplantation[J].Liver Transpl,2007,13(8):1137-1144.
|
|
[15]COFFIN CS,MULROONEY-COUSINS PM,PETERS MG,et al.Molecular characterization of intrahepatic and extrahepatic hepatitis B virus(HBV)reservoirs in patients on suppressive antiviral therapy[J].J Viral Hepat,2011,18(6):415-423.
|
|
[16]CHUN J,KIM W,KIM BG,et al.High viremia,prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence[J].Am J Transplant,2010,10(7):1649-1659.
|
|
[17]FARIA LC,GIGOU M,ROQUE-AFONSO AM,et al.Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation[J].Gastroenterology,2008,134(7):1890-1899;quiz 2155.
|
|
[18]TENG DH,ZHU ZJ,ZHENG H,et al.Clinical analysis of the recurrence of hepatatis B virus-associated hepatocelluar carcinoma after the orthotopic liver transplantation[J].Chin J Organ Transplant,2007,28(12):719-721.(in Chinese)滕大洪,朱志军,郑虹,等.与乙型肝炎病毒相关的原发性肝细胞癌肝移植术后的临床观察[J].中华器官移植杂志,2007,28(12):719-721.
|
|
[19]LI MR,YI SH,CAI CJ,et al.The relationship between hepatocellular carcinoma and hepatitis B virus recurrence after liver transplantation[J].Chin J Hepatol,2011,19(4):271-274.(in Chinese)李敏如,易述红,蔡常洁,等.肝移植术后原发性肝癌复发与乙型肝炎病毒再感染的关系[J].中华肝脏病杂志,2011,19(4):271-274.
|
|
[20]SARRI G,WESTBY M,BERMINGHAM S,et al.Diagnosis and management of chronic hepatitis B in children,young people,and adults:summary of NICE guidance[J].BMJ,2013,346:f3893.
|
|
[21]GAO YJ,LI HW,ZHAO JM,et al.Clinicopathological ananlysis of HBV recurrence in post-liver transplantation patients[J].Chin J Organ Transplant,2011,32(8):477-480.(in Chinese)高银杰,李捍卫,赵景民,等.肝移植后乙型病毒性肝炎复发的临床病理研究[J].中华器官移植杂志,2011,32(8):477-480.
|
|
[22]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[23]WANG ZL,LI H,ZHANG SY,et al.The histologic patterns of common complications following liver transplantation[J].Chin JOrgan Transplant,2008,29(7):417-420.(in Chinese)王政禄,李卉,张淑英,等.肝移植术后常见并发症的病理学特点[J].中华器官移植杂志,2008,29(7):417-420.
|
|
[24]ROCHE B,FERAY C,GIGOU M,et al.HBV DNA persistence 10years after liver transplantation despite successful anti-HBS passive immunoprophylaxis[J].Hepatology,2003,38(1):86-95.
|
|
[25]PESSOA MG,BZOWEJ N,BERENGUER M,et al.Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation[J].Hepatology,1999,30(6):1513-1520.
|
|
[26]FERRARESE A,ZANETTO A,GAMBATO M,et al.Liver transplantation for viral hepatitis in 2015[J].World J Gastroenterol,2016,22(4):1570-1581.
|
|
[27]BENNER KG,LEE RG,KEEFFE EB,et al.Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation[J].Gastroenterology,1992,103(4):1307-1312.
|
|
[28]ZHANG WH,DENG YL,ZHENG H,et al.Clinical analysis of de novo hepatitis B virus infection after liver transplantation[J].Chin J Organ Transplant,2012,33(5):295-298.(in Chinese)张闻辉,邓永林,郑虹,等.肝移植术后新发乙型肝炎病毒感染的临床分析[J].中华器官移植杂志,2012,33(5):295-298.
|
|
[29]SUEHIRO T,SHIMADA M,KISHIKAWA K,et al.Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation[J].Liver Int,2005,25(6):1169-1174.
|
|
[30]MACCONMARA MP,VACHHARAJANI N,WELLEN JR,et al.Utilization of hepatitis B core antibody-positive donor liver grafts[J].HPB(Oxford),2012,14(1):42-48.
|
|
[31]FBREGA E,GARCA-SUAREZ C,GUERRA A,et al.Liver transplantation with allografts from hepatitis B core antibody-positive donors:a new approach[J].Liver Transpl,2003,9(9):916-920.
|
|
[32]HOLT D,THOMAS R,van THIEL D,et al.Use of hepatitis Bcore antibody-positive donors in orthotopic liver transplantation[J].Arch Surg,2002,137(5):572-575;discussion 575-576.
|
|
[33]YU AS,VIERLING JM,COLQUHOUN SD,et al.Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy[J].Liver Transpl,2001,7(6):513-517.
|
|
[34] Chinese Society of Organ Transplantation;Section of Organ Transplantation,Chinese Society of Surgery;Chinese College of Transplant Doctors.The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma(2014 edition)[J].Chin JDig Surg,2014,13(7):497-501.(in Chinese)中华医学会器官移植学分会,中华医学会外科学分会移植学组,中国医师协会器官移植医师分会.中国肝癌肝移植临床实践指南(2014版)[J].中华消化外科杂志,2014,13(7):497-501.
|
|
[35]MARTIN P,DIMARTINI A,FENG S,et al.Evaluation for liver transplantation in adults:2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J].Hepatology,2014,59(3):1144-1165.
|
|
[36]DICKSON RC,TERRAULT NA,ISHITANI M,et al.Protective antibody levels and dose requirements for IV 5%Nabi Hepatitis Bimmune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease[J].Liver Transpl,2006,12(1):124-133.
|
|
[37]WANG K,ZHU ZJ,ZHENG H,et al.Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases[J].Hepatol Res,2012,42(3):280-287.
|
|
[38]LOK AS,McM AHON BJ.Chronic hepatitis B[J].Hepatology,2007,45(2):507-539.
|
|
[39]MARZANO A,GAIA S,GHISETTI V,et al.Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence[J].Liver Transpl,2005,11(4):402-409.
|
|
[40]LUCEY MR,TERRAULT N,OJO L,et al.Long-term management of the successful adult liver transplant:2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J].Liver Transpl,2013,19(1):3-26.
|
|
[41]WANG PJ,TAM N,WANG H,et al.Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation?A meta-analysis[J].PLoS One,2014,9(8):e104480.
|
|
[42]CHOLONGITAS E,PAPATHEODORIDIS GV.High genetic barrier nucleos(t)ide analogue(s)for prophylaxis from hepatitis B virus recurrence after liver transplantation:a systematic review[J].Am JTransplant,2013,13(2):353-362.
|
|
[43]NIU Y,CHEN X,FENG L,et al.Anti-HBc-positive/HBsA gnegative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts[J].Clin Res Hepatol Gastroenterol,2014,38(4):475-480.
|
|
[44]ZHANG HM,SUN LY,ZHENG H,et al.Prognosis of liver retransplantation in patients with viral hepatitis recurrence[J].Chin JDig,2013,33(9):606-610.(in Chinese)张海明,孙丽莹,郑虹,等.病毒性肝炎复发患者再次肝移植的预后[J].中华消化杂志,2013,33(9):606-610.
|
|
[45]TSAI MC,CHEN CH,TSENG PL,et al.Comparison of renal safety and efficacy of telbivudine,entecavir and tenofovir treatment in chronic hepatitis B patients:real world experience[J].Clin Microbiol Infect,2016,22(1):95.e1-e7.
|
|
[46]PRADAT P,LE POGAM MA,OKON JB,et al.Evolution of glomerular filtration rate in HIV-infected,HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate[J].J Viral Hepat,2013,20(9):650-657.
|
|
[47]KELLY DA,BUCUVALAS JC,ALONSO EM,et al.Long-term medical management of the pediatric patient after liver transplantation:2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J].Liver Transpl,2013,19(8):798-825.
|
|
[48]DANZINGER-ISAKOV L,KUMAR D;Practice ASTIDCo.Guidelines for vaccination of solid organ transplant candidates and recipients[J].Am J Transplant,2009,9(Suppl 4):s258-s262.
|
|
[49]ALLEN U,GREEN M.Prevention and treatment of infectious complications after solid organ transplantation in children[J].Pediatr Clin North Am,2010,57(2):459-479,table of contents.
|
|
[50]SU WJ,HO MC,NI YH,et al.Clinical course of de novo hepatitis B infection after pediatric liver transplantation[J].Liver Transpl,2010,16(2):215-221.
|
|
[51]CHANG SH,SUH KS,YI NJ,et al.Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation[J].Hepatology,2003,37(6):1329-1334.
|
|
[52]NI YH,HO MC,WU JF,et al.Response to booster hepatitis B vaccines in liver-transplanted children primarily vaccinated in infancy[J].Transplantation,2008,86(11):1531-1535.
|
|
[53]DONG C,GAO W,MA N,et al.De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation and the treatment[J].Chin J Organ Transplant,2015,36(2):92-96.(in Chinese)董冲,高伟,马楠,等.乙型肝炎核心抗体阳性亲属活体供肝应用于儿童受者的风险及治疗方案[J].中华器官移植杂志,2015,36(2):92-96.
|
|
[54]LEE YJ,OH SH,KIM KM,et al.De novo hepatitis B virus infection after pediatric liver transplantations with hepatitis B core antibody-positive donors:a single-center 20-yr experience[J].Pediatr Transplant,2015,19(3):267-272.
|
|
[55]ISHIGAMI M,HONDA T,ISHIZU Y,et al.Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients[J].Liver Transpl,2014,20(10):1211-1220.
|
|
[56]GNTHER M,NEUHAUS R,BAUER T,et al.Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients:Antibody decline and booster vaccination with conventional vaccine[J].Liver Transpl,2006,12(2):316-319.
|
|
[57]SNCHEZ-FUEYO A,RIMOLA A,GRANDE L,et al.Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination:A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation[J].Hepatology,2000,31(2):496-501.
|
|
[58]YOSHIZAWA A,YAMASHIKI N,UEDA Y,et al.Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen(HBsA g)positive recipients and HBsA g negative recipients of anti-hepatitis B core positive grafts[J].Hepatol Res,2016,46(6):541-551.
|
|
[59]LU SC,JIANG T,LAI W,et al.Reestablishment of active immunity against HBV graft reinfection after liver transplantation for HBV-related end stage liver disease[J].J Immunol Res,2014,2014:764234.
|
|
[60]LO CM,LAU GK,CHAN SC,et al.Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B[J].Am J Transplant,2007,7(2):434-439.
|
|
[61]FENG L,NIU Y,CHEN H,et al.Immunogenicity of different hepatitis B virus vaccination schedules in liver transplant recipients[J].Hepatol Res,2013,43(5):495-501.
|
|
[62]ISHIGAMI M,KAMEI H,NAKAMURA T,et al.Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcA b-positive grafts[J].JGastroenterol,2011,46(3):367-377.
|
|
[63]ROSENAU J,HOOMAN N,HADEM J,et al.Failure of hepatitis B vaccination with conventional HBsA g vaccine in patients with continuous HBIG prophylaxis after liver transplantation[J].Liver Transpl,2007,13(3):367-373.
|
|
[64]di PAOLO D,LENCI I,TRINITO MO,et al.Extended doubledosage HBV vaccination after liver transplantation is ineffective,in the absence of lamivudine and prior wash-out of human Hepatitis Bimmunoglobulins[J].Dig Liver Dis,2006,38(10):749-754.
|
|
[65]KARASU Z,OZACAR T,AKARCA U,et al.HBV vaccination in liver transplant recipients:Not an effective strategy in the prophylaxis of HBV recurrence[J].J Viral Hepat,2005,12(2):212-215.
|
|
[66]ANGELICO M,di PAOLO D,TRINITO MO,et al.Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis[J].Hepatology,2002,35(1):176-181.
|
|
[67]BAUER T,GNTHER M,BIENZLE U,et al.Vaccination against hepatitis B in liver transplant recipients:pilot analysis of cellular immune response shows evidence of HBsA g-specific regulatory Tcells[J].Liver Transpl,2007,13(3):434-442.
|
|
[68]NEVENS F,ZUCKERMAN JN,BURROUGHS AK,et al.Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients[J].Liver Transpl,2006,12(10):1489-1495.
|
|
[69]STRKEL P,STOFFEL M,LERUT J,et al.Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients[J].Liver Transpl,2005,11(10):1228-1234.
|
|
[70]LIN CC,CHEN CL,CONCEJERO A,et al.Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients[J].Am J Transplant,2007,7(1):195-200.
|
DownLoad: